2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine

Affiliations

¹ Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
² Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, Maryland.
³ Department of Hematology and the Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
⁴ Department of Pediatrics, St Louis Children's Hospital, St Louis, Missouri.
⁵ National Institutes of Health, Bethesda, Maryland.
⁶ Department of Laboratory Medicine, Yale University, New Haven, Connecticut.
⁷ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
⁸ Blood Research Institute, Blood Center of Wisconsin, and the Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin.
⁹ Department of Pathology, Brigham and Women's Hospital.
¹⁰ Department of Newborn Medicine, Children's Hospital, Boston, Massachusetts.
¹¹ Washington University in St Louis, St Louis, Missouri.
¹² NHS Blood and Transplant, John Radcliffe Hospital, and Oxford Clinical Research in Transfusion Medicine, Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
¹³ Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
¹⁴ Division of Blood Diseases and Resources, NHLBI/NIH.
¹⁵ National Heart, Lung, and Blood Institute, Bethesda, Maryland.
¹⁶ Division of Laboratory Medicine, Children's National Health System, Washington, DC.

Pablo Cure et al. Transfusion. 2017 Jun.

. 2017 Jun;57(6):1568-1581.

doi: 10.1111/trf.14100. Epub 2017 Mar 28.

¹ Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
² Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, Maryland.
³ Department of Hematology and the Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
⁴ Department of Pediatrics, St Louis Children's Hospital, St Louis, Missouri.
⁵ National Institutes of Health, Bethesda, Maryland.
⁶ Department of Laboratory Medicine, Yale University, New Haven, Connecticut.
⁷ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
⁸ Blood Research Institute, Blood Center of Wisconsin, and the Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin.
⁹ Department of Pathology, Brigham and Women's Hospital.
¹⁰ Department of Newborn Medicine, Children's Hospital, Boston, Massachusetts.
¹¹ Washington University in St Louis, St Louis, Missouri.
¹² NHS Blood and Transplant, John Radcliffe Hospital, and Oxford Clinical Research in Transfusion Medicine, Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
¹³ Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
¹⁴ Division of Blood Diseases and Resources, NHLBI/NIH.
¹⁵ National Heart, Lung, and Blood Institute, Bethesda, Maryland.
¹⁶ Division of Laboratory Medicine, Children's National Health System, Washington, DC.

No abstract available

Figures

1. Brinc D, Denomme GA, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? Curr Opin Hematol 2009;16:488–96. - PubMed
1. Kapur R, Della Valle L, Verhagen OJ, et al. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. Transfusion 2015;55:553–62. - PubMed
1. Bowman J Thirty-five years of Rh prophylaxis. Transfusion 2003;43:1661–6. - PubMed
1. Kumpel BM. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol 2008;154:1–5. - PMC - PubMed
1. Li C, Piran S, Chen P, et al. The maternal immune response to fetal platelet GPIba causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011;121:4537–47. - PMC - PubMed